Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
7,299 total articles
Grab is at an inflection where higher-margin financial services and scaled advertising could materially widen its margins and justify a higher multiple. The stock trades at $3.86 with a market cap of roughly $15.8B, but recent profitability, buyback activity and partnerships (robotaxi trials, delivery automation) give catalysts for re-acceleration.…
Nvidia's dominance in AI compute is shifting from research training to real-world inference. Large enterprise deals, new inference chips, and partnerships (Roche, Cisco, Samsung, Adobe) create a multi-catalyst run. Valuation is rich but pricing already bakes in growth; this trade targets disciplined entry and stop to capture upside as Nebius deploy…
CoreWeave has the demand story investors want: $5.1B in 2025 revenue (168% YoY), a $66.8B backlog, and guidance for $12-13B next year. Recent headline risk - a class action and questions about capital intensity - has driven a knee-jerk pullback. The market is pricing in the wrong risks: demand and contracted backlog look real; financing and executi…
Nvidia’s GTC announcements spooked some investors despite fresh enterprise partnerships and a clear product roadmap. Fundamentals remain strong - $96.7B in free cash flow, ROE north of 76%, near-zero net leverage - and recent partner wins (Roche, Samsung, Adobe, CrowdStrike) support an inference-led revenue surge. I recommend a tactical long entry …
Nvidia's GTC 2026 announcements and a string of enterprise partnerships (Roche, CrowdStrike, Adobe, Samsung) make today a timely entry point for a tactical long. Valuation is rich - but cash flow, low leverage, and tangible commercial deployments justify a measured buy with a clear stop and target.
Novo Nordisk's share price has been punished to $38.62 after a year of GLP-1 headlines and Novo Holdings volatility. The company still sells essential diabetes and obesity medicines, yields 3.19%, and has an active DKK 15 billion buyback. Technicals show an oversold setup with early bullish momentum. This is a tactical long opportunity with defined…
Intuit has been swept up in the broader 'SaaSpocalypse' selloff, yet its mix of subscription cash flow, solid free cash generation ($6.879B last reported), low leverage (debt/equity 0.32) and high switching costs make it a prime contrarian buy. This is an actionable mid-term trade with entry, stop and target, sized for investors willing to take a m…
NOA reported record 2025 revenue of $1.5B and sits on a sizable secured backlog, yet Q4 earnings were hit by a $13M project adjustment and weather-related headwinds. With market cap at ~$377M and a PE of 15.5x, the risk/reward looks favorable for a disciplined long position. This trade plan targets a mid-term rebound while respecting financial leve…
Structure Therapeutics' oral GLP-1 candidate aleniglipron delivered industry-leading Phase 2 weight-loss results on 03/16/2026. With a market cap near $4.0B, an enterprise value around $3.21B and roughly $650M of fresh capital raised late last year, the stock now carries clear acquisition optionality from larger pharma seeking oral GLP-1 exposure. …
AerCap is trading at single-digit earnings multiples, sits well below its 52-week high but comfortably above its 2025 lows, and pays a modest dividend ahead of a March payout. We lay out a focused long trade using a $135.22 entry, a $155 target and a $120 stop. The thesis: cyclical recovery + durable leasing cashflows justify a re-rating; risks inc…
CLPBF looks like a classic compounder that has been punished by low liquidity and heavy short activity rather than by a change in fundamentals. Technical indicators show extreme oversold readings while short interest and short-volume data point to a market dominated by sellers. This trade idea targets mean reversion and liquidity normalization over…
Rivian achieved consolidated gross profitability in 2025, cut per-vehicle costs, and is set to begin R2 deliveries in April with >100,000 reservations. With a $19B market cap and EV/sales near 3.7, the stock offers asymmetric upside if R2 execution and margin expansion continue. This is a structured long trade for swing traders looking to capture t…
Venture Global (VG) is a high-conviction swing trade following an Iran-related supply shock that sent European LNG prices sharply higher. With a meaningful portion of 2026 output exposed to spot pricing, recent earnings beat and strong EBITDA guidance, and attractive valuation on an EV/EBITDA basis, VG looks positioned to capture a multi-week rebou…
Fastenal (FAST) runs a sticky industrial distribution business with high returns and strong free cash flow, yet is trading at premium multiples (P/E ~41.7, P/B ~13.3, EV/EBITDA ~28.4). For traders, the setup today favors a tactical short/swing trade: valuation-sensitive downside exists over the next several weeks if industrial activity softens or e…
Blue Owl (OWL) has been punished for private credit headlines and a temporary redemption freeze, but a close look at cash flow, valuation and balance-sheet mechanics suggests much of the bad news is priced in. This trade backs a recovery from current levels with defined risk-management: entry $8.70, stop $7.50, first target $12 (mid term, 45 tradin…
Qualcomm's smartphone revenue softness has pressured the stock, but accelerating automotive content, Wi‑Fi/IoT demand and strong free cash flow create a high-probability swing trade. Technicals show oversold conditions and short interest has ticked up, offering a defined reward-to-risk trade for the next 45 trading days.
Shell (SHEL) offers a pragmatic, income-oriented long trade: collect the dividend, benefit from an active buyback program and a still-recovering oil-cycle tailwind. Technical momentum is strong but short-term indicators are stretched; a disciplined entry, stop and target limit downside for a 180-trading-day position.
Vertiv remains one of the purest pick-and-shovel plays on the AI data center buildout. With a $15B backlog, 252% year-over-year organic order growth, and S&P 500 inclusion creating near-term buying pressure, the stock offers an actionable long setup. Valuation is rich but supported by strong free cash flow and improving margins; this idea is a medi…
Pagaya is trading like a growth company that forgot how to trade — cheap on earnings and cash flow, backed by improving fundamentals and a strategic pivot toward an asset-light AI platform. With a market cap of roughly $907M, P/E ~11.7 and P/FCF ~4.04, Pagaya looks like a deep-value swing trade for disciplined buyers. This note lays out a concrete …
Coffee Holding (JVA) punched up ~18% to $3.73 on heavy volume as the market priced in materially improved near-term prospects. At ~ $18.1M market cap, the stock trades at a P/E near 13, P/B ~0.66 and EV/EBITDA ~8.2 - cheap for a cash-generating roaster with low leverage. I rate JVA Strong Buy for a mid-term swing: entry $3.73, target $5.63 (52-week…
We reaffirm a Buy on Alcon (ALC). The STAAR merger setback is a headline, not a thesis-breaker: Alcon’s core Surgical and Vision Care franchises generate durable cash flow, the balance sheet is conservative, and a pending LENSAR deal plus broad ophthalmic market growth create upside catalysts. Technicals look oversold — present an entry — but the t…
Palvella’s QTORIN topical platform is targeting multiple rare dermatologic and vascular malformations with no FDA-approved therapies. Recent positive Phase 2 data, a completed upsized $230M offering and a small public float create a volatile but actionable setup. This trade proposes a long position at current levels with a defined stop and upside t…
Sonoco (SON) looks attractive as a mid-term long trade: low valuation (P/E ~5.2), solid free cash flow and announced April price increases in paperboard create a clear earnings upside. Entry $53.70, stop $50.00, target $63.00 over ~45 trading days.
UnitedHealth ($UNH) is showing technical signs of stabilization after a difficult 2025. Fundamentals still look solid - market cap about $259B, free cash flow roughly $17.4B and EV/EBITDA near 10 - but regulatory and cost pressures leave upside capped until execution visibly improves. This trade idea outlines a guarded, short-biased swing to captur…
Zeta's acquisition of Marigold gives the company more addressable data and product depth at a reasonable enterprise value. The combination improves near-term cash generation and raises the upside for a mid-term trade. Entry at $17.90, stop at $16.25, target $22.50 — mid-term (45 trading days) thesis with a medium risk profile.
